Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the risk of developing cancer, especially colorectal and endometrial cancers

NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognise and eliminate cancer before tumours develop.

Full safety and immunogenicity results from a Phase Ib/II study of NOUS-209 in LS to be presented in an oral presentation at AACR 2025

Following positive meetings with FDA, NOUS-209 clinical data support advancement to a potentially registration-enabling clinical study for cancer interception in LS

https://www.globenewswire.com/news-release/2025/3/25/3049177/0/en/Nouscom-to-Present-Final-Results-from-Successful-Phase-Ib-II-Trial-of-NOUS-209-in-People-Living-with-Lynch-Syndrome-Demonstrating-Powerful-Potential-to-Intercept-Cancer-in-its-Earl.html